cbd.u stock

HempFusion Wellness Enters China with Probulin Probiotics Through Alibaba Group's Tmall Global, Reaching More Than 750 Million Potential New Consumers

HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO) ("HempFusion" or the "Company"), a leading health and wellness company offering premium probiotic supplements and products containing CBD, is pleased to announce the launch of certain products through its wholly-owned subsidiary, Probulin Probiotics, LLC ("Probulin"), on Alibaba Group Holding's Tmall Global ("Tmall"), the world's largest cross border online marketplace reaching more than 750 million consumers in mainland China, Hong Kong, Macau and Taiwan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005195/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

"This strategic launch provides us with a tremendous opportunity to reach one of the largest online consumer bases in the world and drive significant revenue for the Company," said Jon Visser, HempFusion's Chief Revenue Officer.

With shipments expected to begin early next week, HempFusion expects its Probulin products to be available for purchase on Tmall with a go live date currently set at March 29, 2021, ahead of one of China's largest single day shopping extravaganzas, the mid-year 618 shopping festival, which shattered records last year with more than USD$98.52 billion in single day sales.

The Probulin products expected to be made available online through Tmall in greater China will include Total Care Immune , Total Care , Daily Care , Women's Health , Colon Support and My Little Bugs™ Total Care Probiotic For Kids .

Tmall regularly engages consumers with brands through livestreaming, educational videos and group chats. "Probulin looks forward to utilizing our growing team of celebrity influencers to take advantage of these innovative, interactive opportunities to reach new consumers in a fun and entertaining way. Additionally, we look forward to launching more of our brands in China through Tmall in the near future," continued Mr. Visser.

In 2020, health supplements and probiotics were among the most popular categories on the Tmall platform.

"Launching in China is a tremendous milestone and an unparalleled opportunity to educate the enormous Chinese market on the many health benefits of probiotics," stated Dr. Jason Mitchell, N.D., HempFusion's Co-Founder and CEO. "At Probulin, we stand on integrity, offering only the highest quality products and radical transparency throughout the entire process."

"We believe Probulin to be the first American company to deliver cold and protected probiotic supplements direct to Chinese consumers," continued Dr. Mitchell. "In addition, our scientifically validated MAKTrekⓇ 3-D Probiotic Delivery System is designed to protect and nourish the probiotics so that more can arrive alive in the gut. These two distinguishing factors result in a positive influence on the microbiome and overall wellness."

Recognized as one of the fastest-growing probiotics brands in the United States by SPINs syndicated data, HempFusion's Probulin products are available in eight countries around the world and represent the next generation of probiotics for digestive health and immune support based entirely on cultured food and scientifically studied strains.

ABOUT HEMPFUSION

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion's diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion's wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion's CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com .

Follow HempFusion on Twitter , Facebook and Instagram and Probulin on Twitter , Facebook and Instagram .

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, " forward-looking statements ") that relate to HempFusion's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result", "are expected to", "expects", "will continue", "is anticipated", "anticipates", "believes", "estimated", "intends", "plans", "forecast", "projection", "strategy", "objective" and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the launch of the Company's Probulin products on Tmall and the timing and revenue opportunity thereof, planned launch of the Company's additional brands in China and the Company's other plans, focus and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under " Forward-Looking Statements " and " Risk Factors " in the final long form prospectus of the Company dated December 17, 2020 and available under the Company's profile on SEDAR at www.sedar.com . HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Jason Mitchell, N.D.
Chief Executive Officer and Director
Email: ir@hempfusion.com
Phone: 416-803-5638

News Provided by Business Wire via QuoteMedia

The Conversation (0)

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

Findings From Tezspire ® (tezepelumab-ekko) Phase 2a COURSE COPD Study

Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Quarterly Activities/Appendix 4C Cash Flow Report

BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”), a plant-based biotechnology company, today released its Appendix 4C and Quarterly Activities Report for the period ended 31 March 2024.

Keep reading...Show less
Hydralyte

Q1 FY24 Quarterly Report and Appendix 4C: 43% Reduction in YoY Net Operating Cash Use to Record Low

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte North America or the Company) is pleased to provide the following update on its operational and financial performance for the three-month period ended 31 March 2024 (the “quarter”).

Keep reading...Show less
Medical capsule and transparent cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness and swelling. 1 If approved, teprotumumab would be the first and only medicine approved for TED in the European Union.

"We are enthusiastic to bring a much-needed medicine to the Thyroid Eye Disease community in Europe by leveraging Amgen's strong reputation and broad infrastructure in the region," said Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen. "This disease is currently managed with steroids and invasive surgeries, both of which carry their own set of risks. Having access to a non-surgical option like teprotumumab that not only treats the signs and symptoms, but also targets the underlying cause of the disease represents a major advance for patients."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×